The 12.2% de novo germline mutation rate in MMR genes and other non-CRC cancer susceptibility genes (BRCA1, BLM, and NTHL1) reported herein for the young sporadic CRC group is reasonable and expectable. This evidence concerns the gene BRCA1 and colorectal carcinoma.